>…so let me guess this straight, there are two glycoforms of AT produced in transgenic goats, one form that is essentially bio-equivalent to pAT, and another form that is more rapidly cleared.<
This is inaccurate on two counts:
1. Both ATryn and endogenous AT have two isoforms: AT-alpha and AT-beta. The beta isoform has a shorter half-life. In endogenous AT (and plasma-derived AT), the alpha isoform comprises 90-95% of total AT and the beta isoform comprises 5-10%:
In ATryn, the beta isoform comprises considerably more than 10% of total AT (but GTC has not publicly disclosed the actual number). This is what gives ATryn a shorter half-life than plasma-derived AT.
2. To my knowledge, the two isoforms of AT are not variant glycoforms, as you assumed. Thus, the PK difference between ATryn and plasma-derived AT is not a glycosylation issue.
Market Data 
Markets 
AI
